Scipher Medicine, a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies, has appointed Jerry Conway as Senior Vice President of Market Access. He will focus on patient access to Scipher’s precision diagnostic tools beginning with PrismRA®, a first-of-its-kind molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid arthritis (RA), which is expected to launch later this year.
“Too many patients are prescribed medications that never had a chance of working for them based on their unique biology,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “I am confident that our strong leadership team with the addition of Jerry has the power to change that. Jerry will be instrumental in ensuring our molecular signature tests are widely available to the patients who need them as we lead the effort to bringing precision medicine to patients with complex diseases, starting with autoimmune.”
Conway brings more than 30 years of experience in the reimbursement of novel molecular diagnostic platforms, having obtained broad payer coverage with value-based payment from Medicare, employers and commercial payers. He has built an illustrious career of working with key payers to ensure product coverage upon market launch at companies such as Foundation Medicine, Genzyme Genetics and Corning Metpath. Most recently, Conway was the Executive Vice President at CDx Diagnostics.
“Constant drug cycling from patients prescribed ineffective medications hurts patients, our healthcare utilization and payers across the board,” said Conway. “Scipher’s technology has the power to change that, and it is my honor to work on this endeavor for the good of patients and our healthcare ecosystem.”
About Scipher Medicine
Scipher Medicine, a molecular data company founded on the principles of Network Medicine, holds the fundamental belief that patients deserve answers to their treatment options using scientifically backed data. With artificial intelligence and its proprietary molecular technology platform, Scipher Medicine develops diagnostic tests that analyze patients’ unique molecular signatures to accurately predict response to targeted therapeutics. By amassing the data from these tests, the company develops more effective therapies.
Scipher Medicine is privately held, headquartered in Waltham, Massachusetts and backed by Khosla Ventures, Northpond Ventures and UnitedHealth Group. To learn more, visit ScipherMedicine.com and follow Scipher on Twitter and LinkedIn.